Module 7 - Part 2 of 8

Patent Litigation

Understand the complexities of patent infringement suits, invalidity defenses, claim construction principles, expert evidence requirements, and damages computation in India's pharmaceutical patent litigation landscape.

Duration: 75-90 minutes

7 Key Topics

10 Quiz Questions

Topic 1

Infringement Suits under Patents Act

Patent infringement litigation in India is governed primarily by Sections 104-114 of the Patents Act, 1970. Understanding the procedural and substantive requirements is essential for effective patent enforcement.

Section 48: Rights of Patentee

A patent grants the patentee the exclusive right to:

Product Patent: Prevent third parties from making, using, offering for sale, selling, or importing the patented product
Process Patent: Prevent third parties from using the process, and from using, offering for sale, selling, or importing the product directly obtained by that process

Who Can Sue for Infringement?

Patentee: The registered owner of the patent
Exclusive Licensee: Licensee with exclusive rights can sue in their own name (Section 109)
Co-owners: Each co-owner can sue without joining others, but must notify them
Assignee: Assignee of patent rights can sue after recording assignment

Key Concept: Section 104 - Jurisdiction

Patent infringement suits must be filed in a District Court or High Court. No court inferior to a District Court has jurisdiction. The suit can be filed where:

The defendant resides or carries on business
The cause of action arises (where infringement occurs)
The plaintiff carries on business (additional jurisdiction under proviso)

Types of Patent Infringement

Direct Infringement

When a person makes, uses, sells, or imports the patented invention without authorization. The product or process must fall within the scope of at least one claim of the patent.

Contributory Infringement

While not explicitly recognized in Indian law, courts have considered situations where a party supplies components knowing they will be used to infringe a patent.

Literal Infringement

When the accused product or process contains every element recited in the patent claim, literally interpreted.

Doctrine of Equivalents

Infringement even when the accused product differs from the patent claim if it performs substantially the same function in substantially the same way to achieve substantially the same result.

Reliefs Available

Under Section 108, the following reliefs are available in infringement suits:

Injunction: Permanent injunction restraining infringement
Damages or Account of Profits: Plaintiff can elect between the two
Delivery up: Seizure of infringing products and materials
Costs: Legal costs as determined by the court

Topic 2

Invalidity Defense and Counterclaims

The invalidity defense is the most common and powerful defense in patent infringement suits. A defendant can challenge the validity of the patent as a shield against infringement claims or file a counterclaim for revocation.

Section 107: Defenses in Infringement Suits

In any suit for infringement, every ground on which a patent may be revoked under Section 64 shall be available as a ground for defense. Key grounds include:

The invention was publicly known or publicly used in India before the priority date
The invention was published in India or elsewhere before the priority date
The invention is obvious and does not involve an inventive step
The subject matter is not patentable under Section 3 or Section 4
The complete specification does not sufficiently describe the invention
The claims are not fairly based on the matter disclosed in the specification

Counterclaim for Revocation

Under Section 64(1), a defendant can file a counterclaim seeking revocation of the patent. This converts the suit into both an infringement case and a revocation proceeding heard together.

Key Concept: Burden of Proof

In infringement proceedings, the burden of proof shifts depending on the nature of defense:

Infringement: Plaintiff must prove infringement on balance of probabilities
Invalidity: Defendant must prove invalidity - the patent enjoys presumption of validity once granted
Process Patent (Section 104A): For process patents relating to new products, the burden shifts to the defendant to prove their process is different

Common Invalidity Grounds

Lack of Novelty (Anticipation)

The invention was known or used publicly before the priority date. A single prior art document disclosing all elements of the claim can anticipate the patent.

Obviousness

The invention does not involve an inventive step. A person skilled in the art could have arrived at the invention combining prior art references with common general knowledge.

Section 3(d) Challenge

In pharmaceutical cases, the defendant may argue that the patent claims a mere new form, new use, or new property of a known substance without enhanced efficacy.

Insufficient Disclosure

The specification does not describe the invention clearly and completely enough for a skilled person to perform it.

Practical Strategy: Invalidity vs. Non-Infringement

Defendants must carefully consider whether to pursue invalidity, non-infringement, or both:

Risk of Estoppel: Arguments made in invalidity may impact non-infringement position
Claim Construction: Narrow construction helps non-infringement but weakens invalidity
Prior Art Quality: Strong prior art makes invalidity preferable
Market Position: Invalidity benefits all competitors; non-infringement is defendant-specific

Topic 3

Claim Construction Principles

Claim construction is the process of interpreting the meaning and scope of patent claims. It is often the pivotal issue in patent litigation as it determines both infringement and validity analysis.

Key Concept: Claims Define the Monopoly

The claims of a patent define the scope of the monopoly granted. Under Section 10(4)(c), the claims must "define the scope of the invention for which protection is claimed" and be "clear, succinct and fairly based on the matter disclosed in the specification."

Principles of Claim Interpretation

Purposive Construction: Claims should be interpreted to give effect to the inventor's purpose as understood by a skilled person
Specification as Dictionary: The specification provides context and definitions for claim terms
Ordinary Meaning: Claim terms carry their ordinary meaning unless the specification provides a different definition
Consistent Interpretation: Claims should be construed consistently for both infringement and validity
All Limitations: Every element in the claim must be given meaning; no element is superfluous

Interpretation Resources

Courts may consider the following when construing claims:

Intrinsic Evidence: Claims, specification, drawings, prosecution history
Extrinsic Evidence: Expert testimony, technical dictionaries, prior art references
Prosecution History: Amendments and arguments made before the Patent Office

Intrinsic evidence is generally given more weight than extrinsic evidence.

Indian Approach to Claim Construction

Indian courts have developed claim construction principles drawing from both UK and US jurisprudence:

Case Law: F. Hoffmann-La Roche v. Cipla (2008)

The Delhi High Court extensively discussed claim construction principles:

Claims must be read in the context of the entire specification
The preamble of a claim is part of the claim and cannot be ignored
Technical terms must be given their technical meaning as understood by persons skilled in the art
The doctrine of equivalents may expand claim scope beyond literal meaning

Doctrine of Equivalents in India

Indian courts have recognized the doctrine of equivalents, though its application remains developing:

Applies when the accused product is not literally within the claim but is substantially equivalent
The function-way-result test is commonly applied
Prosecution history estoppel may limit equivalents
Cannot be used to cover prior art or matter disclaimed during prosecution

Topic 4

Expert Evidence in Patent Cases

Expert evidence is crucial in patent litigation due to the technical nature of patent disputes. Understanding the role, qualification, and presentation of expert testimony is essential for patent practitioners.

Role of Expert Witnesses

Claim Construction: Explaining how a person skilled in the art would understand claim terms
Infringement Analysis: Comparing the accused product/process with patent claims
Validity Assessment: Analyzing prior art and obviousness
Damages Calculation: Computing lost profits or reasonable royalty
Technical Background: Educating the court on the technology

Key Concept: Person Skilled in the Art (PSITA)

The hypothetical "person skilled in the art" is central to patent analysis. The expert helps establish:

The relevant field of the invention
The level of education and experience of a PSITA
Common general knowledge in the field
How a PSITA would understand claim terms and prior art

Qualification of Patent Experts

Technical Expertise

The expert should have education and experience in the relevant technical field. For pharmaceutical patents, this typically means chemistry, pharmacology, or related disciplines.

Independence

Experts must be independent and not have a personal interest in the outcome. Financial relationship with the party does not disqualify but affects credibility.

Contemporaneous Knowledge

For validity analysis, the expert should be able to testify about the state of knowledge at the priority date, not current knowledge.

Presentation of Expert Evidence

Expert Report: Written report setting out qualifications, methodology, and opinions
Examination-in-Chief: Direct testimony explaining opinions
Cross-examination: Testing the expert's opinions and methodology
Hot-Tubbing: Concurrent expert testimony where experts from both sides testify together (increasingly used in Delhi High Court)

Section 45, Indian Evidence Act

"When the Court has to form an opinion upon a point of foreign law or of science or art, or as to identity of handwriting or finger impressions, the opinions upon that point of persons specially skilled in such foreign law, science or art, or in questions as to identity of handwriting or finger impressions are relevant facts."

Patent cases typically involve science and art, making expert opinions admissible and often essential.

Topic 5

Interim Relief in Patent Matters

Interim injunctions in patent cases present unique challenges due to the technical complexity and public interest considerations, particularly in pharmaceutical cases affecting access to medicines.

Three-Factor Test for Interim Injunction

Prima Facie Case

The plaintiff must show a reasonable probability of success at trial. In patent cases, this includes prima facie validity of the patent and prima facie infringement.

Irreparable Injury

Harm that cannot be adequately compensated by damages. Market erosion, price reduction, and loss of exclusivity period may constitute irreparable harm.

Balance of Convenience

Comparison of hardship to plaintiff if injunction refused versus hardship to defendant if injunction granted. Public interest is a significant factor.

Landmark Case: F. Hoffmann-La Roche v. Cipla (2008)

This case established important principles for interim relief in pharmaceutical patent cases:

The Delhi High Court refused interim injunction despite finding prima facie infringement
Public interest in access to cancer medication (Erlotinib) weighed against injunction
Price difference between patented and generic version (Rs. 4,800 vs Rs. 1,600 per tablet) was a relevant factor
The court directed Cipla to maintain accounts and provide security

This case signaled that Indian courts would balance patent rights against public health considerations.

Public Interest Considerations

Indian courts have developed a nuanced approach to interim relief in pharmaceutical cases:

Life-Saving Drugs: Greater reluctance to grant injunctions for essential medicines
Price Differential: Significant price difference between patented and generic affects balance of convenience
Market Availability: Whether alternative treatments are available at affordable prices
Development Stage: Whether generic is already in market versus preparing to launch

Protective Orders in Lieu of Injunction

When courts refuse interim injunction, they often impose protective conditions:

Maintenance of detailed accounts of sales
Furnishing security/bank guarantee for potential damages
Periodic disclosure of sales data
Undertaking not to export to certain markets
Marking products as "subject to patent litigation"

Topic 6

Damages Computation in Patent Cases

Section 108 of the Patents Act provides for damages or account of profits as remedies for infringement. Understanding damages computation is crucial for both enforcement and defense strategies.

Types of Monetary Relief

Compensatory Damages

Damages to compensate the patentee for losses suffered due to infringement. Aims to put the patentee in the position they would have been but for the infringement.

Account of Profits

Alternative to damages - the patentee can claim the infringer's profits attributable to the infringement. Requires election between damages and account of profits.

Damages Computation Methods

Lost Profits: Profits the patentee would have made but for the infringement
- Requires proof of demand, manufacturing capacity, and absence of non-infringing alternatives
- Must establish "but for" causation
Reasonable Royalty: Hypothetical license fee that willing parties would have agreed
- Based on industry licensing rates
- Considers the value of the patented feature
- Often used when lost profits cannot be proven
Price Erosion: Reduction in prices caused by infringer's competition
Market Share Loss: Sales diverted from patentee to infringer

Key Concept: Election Between Damages and Account of Profits

The patentee must elect between damages and account of profits - they cannot claim both. Factors affecting election:

Infringer's profit margins versus patentee's lost profits
Evidence availability for each computation
Volume of infringing sales versus patentee's capacity
Market expansion by infringer

Damages in Indian Courts

Indian courts have historically been conservative in awarding damages in patent cases. Key observations:

Damages awards have been relatively modest compared to Western jurisdictions
Detailed damages discovery is still developing
Courts often rely on account of profits due to evidentiary difficulties
Recent cases show increasing sophistication in damages analysis

Topic 7

Landmark Patent Cases

Several landmark cases have shaped patent litigation practice in India, particularly in the pharmaceutical sector. Understanding these precedents is essential for patent practitioners.

F. Hoffmann-La Roche v. Cipla (2008-2016)

Subject: Erlotinib (cancer drug) patent infringement

Key Holdings:

Established public interest as crucial factor in interim relief for pharmaceutical patents
Recognized that patent rights must be balanced against right to health
Set precedent for protective orders in lieu of injunction
Eventually settled with Roche withdrawing from Indian market

Impact: Signaled that India would take a nuanced approach to pharmaceutical patent enforcement.

Merck v. Glenmark (2015)

Subject: Sitagliptin (diabetes drug) patent infringement

Key Holdings:

Delhi High Court granted interim injunction in favor of Merck
Court found strong prima facie case of infringement
Glenmark's invalidity defense was not found to be credible at interim stage
First major interim injunction granted in pharmaceutical patent case

Impact: Demonstrated that injunctions are available in appropriate cases even for pharmaceutical patents.

Novartis v. Union of India (2013)

Subject: Imatinib Mesylate (Glivec) patent application under Section 3(d)

Key Holdings (Supreme Court):

Section 3(d) is a valid provision and not TRIPS-violative
"Efficacy" in Section 3(d) means therapeutic efficacy for pharmaceutical substances
New forms of known substances require significantly enhanced efficacy
Physico-chemical properties alone do not constitute enhanced efficacy

Impact: Landmark ruling on patentability standards for pharmaceuticals in India.

Bayer v. Natco (2012-2014)

Subject: First compulsory license granted in India for Sorafenib (cancer drug)

Key Holdings:

Patent Controller granted compulsory license under Section 84
Upheld by IPAB and Bombay High Court
Royalty fixed at 6% of net sales
All three grounds under Section 84(1) were found satisfied

Impact: First compulsory license demonstrates India's willingness to use TRIPS flexibilities.

Key Principles from Landmark Cases

Public interest is a relevant factor in IP enforcement, not just an abstract concept
Indian courts will scrutinize pharmaceutical patents carefully under Section 3(d)
Interim injunctions are available but subject to balance of convenience including public health
TRIPS flexibilities including compulsory licensing are part of India's policy toolkit
Protective orders can balance patentee and public interests pending trial

Test Your Knowledge

Part 2 Quiz

Answer the following 10 questions to test your understanding of Patent Litigation.

Question 1 of 10

Under Section 104A of the Patents Act, when does the burden of proof shift to the defendant?

A) In all product patent cases
B) In process patent cases where the product is new
C) In all infringement cases
D) Only in pharmaceutical patent cases

Explanation:

Section 104A provides that in infringement proceedings for process patents where the product obtained by the process is NEW, the burden shifts to the defendant to prove that their product was not obtained by the patented process. This recognizes the difficulty in proving process infringement.

Question 2 of 10

Which section of the Patents Act provides that every ground for revocation is available as a defense in infringement suits?

A) Section 64
B) Section 104
C) Section 107
D) Section 108

Explanation:

Section 107 provides that in any suit for infringement of a patent, every ground on which the patent may be revoked under Section 64 shall be available as a ground for defense. This allows defendants to challenge validity without filing a separate revocation petition.

Question 3 of 10

In F. Hoffmann-La Roche v. Cipla, the Delhi High Court refused interim injunction primarily because of:

A) Public interest in access to cancer medication
B) The patent was found invalid
C) No infringement was established
D) Cipla had a prior license

Explanation:

The court found prima facie infringement but refused interim injunction on public interest grounds. The significant price difference between Roche's product and Cipla's generic, and the nature of the drug (cancer medication), tipped the balance of convenience against granting an injunction.

Question 4 of 10

The "doctrine of equivalents" allows patent infringement to be found when:

A) The defendant copies the patent exactly
B) The defendant obtains a similar patent
C) The defendant licenses the technology
D) The accused product performs substantially the same function in substantially the same way

Explanation:

The doctrine of equivalents expands patent protection beyond literal claim language. Infringement is found if the accused product performs substantially the same function, in substantially the same way, to achieve substantially the same result (the function-way-result test).

Question 5 of 10

Under Section 108 of the Patents Act, a patentee can claim:

A) Both damages and account of profits
B) Either damages or account of profits
C) Only injunction relief
D) Triple damages for willful infringement

Explanation:

Section 108 provides relief by way of injunction, damages or account of profits. The plaintiff must elect between damages and account of profits - they cannot claim both. This differs from some jurisdictions where enhanced damages may be available.

Question 6 of 10

In Novartis v. Union of India (2013), the Supreme Court held that "efficacy" under Section 3(d) for pharmaceuticals means:

A) Chemical efficacy
B) Manufacturing efficacy
C) Therapeutic efficacy
D) Commercial efficacy

Explanation:

The Supreme Court held that for pharmaceutical substances, "efficacy" in Section 3(d) means therapeutic efficacy - the ability of the drug to treat the disease it is intended for. Improved physico-chemical properties alone do not constitute enhanced efficacy.

Question 7 of 10

Who can file a suit for patent infringement?

A) Patentee or exclusive licensee
B) Only the patentee
C) Any licensee
D) Only the inventor

Explanation:

The patentee (registered owner) can always sue for infringement. Under Section 109, an exclusive licensee can also institute a suit for infringement in their own name. Non-exclusive licensees cannot sue without joining the patentee.

Question 8 of 10

In Bayer v. Natco, the first compulsory license in India was granted under:

A) Section 82
B) Section 92
C) Section 92A
D) Section 84

Explanation:

The compulsory license was granted under Section 84, which allows any person to apply for compulsory license after three years from grant if: (a) reasonable requirements of public not satisfied, (b) not available at reasonably affordable price, or (c) not worked in India.

Question 9 of 10

"Hot-tubbing" in patent litigation refers to:

A) A method of claim construction
B) Concurrent expert testimony
C) Chemical testing of samples
D) Settlement negotiation process

Explanation:

Hot-tubbing is a procedure where expert witnesses from both sides testify concurrently, allowing them to discuss issues together and respond to each other's views directly. This has been increasingly used in the Delhi High Court for complex technical disputes.

Question 10 of 10

Which of the following is NOT a type of patent infringement?

A) Literal infringement
B) Infringement by equivalents
C) Anticipatory infringement
D) Direct infringement

Explanation:

"Anticipatory infringement" is not a recognized type of infringement. Anticipation is a ground for invalidity (prior art anticipates the patent), not a type of infringement. Literal infringement, infringement by equivalents, and direct infringement are recognized types.